Terms ending in 2039
Every in-force patent on Element Biosciences, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,704,094 | Multipart Reagents Having Increased Avidity for Polymerase Binding In force · High confidence | Element Biosciences, Inc. | In force | High confidence | |
| US 10,876,148 | De Novo Surface Preparation and Uses Thereof In force · High confidence | Element Biosciences, Inc. | In force | High confidence | |
| US 10,982,280 | Multipart Reagents Having Increased Avidity for Polymerase Binding In force · High confidence | Element Biosciences, Inc. | In force | High confidence | |
| US 12,313,627 | Multivalent Binding Composition for Nucleic Acid Analysis In force · High confidence | Element Biosciences, Inc. | In force | High confidence | |
| US 10,768,173 | Multivalent Binding Composition for Nucleic Acid Analysis In force · High confidence | Element Biosciences, Inc. | In force | High confidence | |
| US 12,134,766 | Methods for Generating Circular Nucleic Acid Molecules In force · High confidence | Element Biosciences, Inc. | In force | High confidence | |
| US 11,426,732 | Flow Cell Device and Use Thereof In force · Medium confidence | Element Biosciences, Inc. | In force | Medium confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.